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ABSTRACT
Background: During lung surgeries, one-lung ventilation (OLV) produces severe ventilation and
perfusion abnormalities that can delay patient recovery. Recent articles suggest that
Dexmedetomidine may have protective effects on the lungs when hypoxic conditions exist and
may improve hypoxic pulmonary vasoconstriction. Additional literature review is needed to
confirm the reproducibility of these findings and generate evidence-based practice
recommendations regarding the usage of Dexmedetomidine as an anesthesia adjunct during onelung ventilation.
Aim: This literature review aims to assess the best randomized control trials (RCTs) available
regarding the benefits of Dexmedetomidine (DEX) coadministration during one-lung ventilation
for pulmonary surgeries. By analyzing current evidence, the authors strive to introduce
recommendations for anesthesia professionals that will reduce the prevalence of hypoxia and
ventilation/perfusion abnormalities during pulmonary surgeries.
Study Selection: Seven RCTs, totaling 419 subjects, were included in this literature review and
selected based upon their inclusion of adult human participants undergoing general anesthesia
with one-lung ventilation for pulmonary surgeries, written in the English language, from 1999 to
2020, published in scientific/peer-reviewed journals and available for download from the
CINAHL, Medline, and EMBASE databases
Results: Six of the seven RCTs reviewed reported improved oxygenation amongst the group
receiving Dexmedetomidine compared to the control; however, only four studies could establish
statistical significance. One article observed a reduction in PaO2 in the DEX group that did not
achieve statistical significance. After distribution of the literature review via an online
educational module, the number of anesthesia providers “very likely” to implement DEX
coadministration during OLV increased between the pre-test (n=2) and post-test (n=4).
Conclusion: Current evidence suggests that Dexmedetomidine coadministration with Propofol or
inhalational anesthetic agents during one-lung ventilation will improve oxygenation
intraoperatively. The mechanisms through which these benefits occur remains a debate and
should be the focus of future research. After receiving a virtual module on the evidence gathered,
more anesthesia providers indicate they are “very likely” to incorporate Dexmedetomidine during
these types of surgery, signifying willingness to implement evidence-based practice changes.
Keywords: one-lung ventilation, lung isolation, single lung ventilation, hypoxic pulmonary
vasoconstriction, oxygenation, lung surgery, precedex, Dexmedetomidine, anesthesia
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INTRODUCTION
Description of Problem
In 2020 there were approximately 228,820 new cases of lung cancer diagnosed in the
United States alone.1 Lung cancer is the second most common type of cancer in both men and
women, and each year more people die from lung cancer than colon, breast, and prostate cancers
combined. 1 Non-small cell lung cancer accounts for 85% of all lung cancer diagnoses and over
half of people with this condition die within one year of discovery.2 Because of the aggressive
nature of this disease, early surgical intervention is recommended as the standard of care.2
Although frequently performed, lung surgeries are not without complications. Following
thoracic surgeries, patients frequently experience complications from atelectasis, pneumonia,
atrial fibrillation, and require chest tube placement for several days.3 Failure to optimize
respiratory function and control pain are the two most significant risk factors for postoperative
complications that increase the length of stay3; therefore, research should focus on these areas to
improve patient outcomes. In 2008, a video-assisted thoracoscopic (VATS) lobectomy cost
approximately $20,316, which may also highlight a significant financial incentive to reduce
length of stay and decrease insurance expenditures for lung surgeries.4 The prevalence of
minimally invasive VATS procedures has increased five-fold within the last decade;5 therefore, it
is imperative to identify anesthesia techniques that improve oxygenation and reduce pain during
these procedures to minimize recovery times for these patients.
Background
Surgical procedures involving the lungs, such as pneumonectomies, lobectomies,
segmental wedge resections, and VATS, require the operative lung to remain motionless during
surgery. Forcing the lung to remain still for surgery naturally creates a problem with maintaining
oxygenation; therefore, anesthetists must be familiar with how to respond to the physiological
changes that occur during these procedures. Specific anesthetic techniques, known as lung
isolation or one-lung ventilation (OLV), utilize special endobronchial tubes to allow a patient to
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breathe through one lung while the other lung is held still for surgery. While the operative lung
lies motionless and no longer participates in gas exchange, a hypoxic environment may persist
and inflammatory changes within the lungs may occur that ultimately delay the patient’s
postoperative recovery.
Natural protective mechanisms, such as hypoxic pulmonary vasoconstriction (HPV),
exist to counteract these problems during one-lung ventilation by constricting pulmonary blood
vessels so that more blood flows to the oxygenated lung.6 Shifting pulmonary blood flow to areas
of the lungs that are better ventilated allows for more diffusion of oxygen into the bloodstream
and ultimately improves oxygen delivery to organs and tissues. The preservation of hypoxic
pulmonary vasoconstriction is important for maintaining normal oxygenation during lung
surgeries; however, several of the most common anesthetic agents used to provide hypnosis and
limit responses to surgical stimulation can impair HPV. Anesthesia providers must understand
how to develop an appropriate plan of care which provides sufficient anesthesia while also
implementing steps to preserve HPV and improve oxygenation during these surgeries.
Anesthetic interventions to prevent desaturation during OLV primarily revolve around
ventilation strategies, maintaining hemodynamic stability, and titration of anesthetic medications
to preserve HPV.7 Volatile anesthetic agents (VAAs) Desflurane, Isoflurane, and Sevoflurane, as
well as the intravenous medicine Propofol, are commonly used for maintenance of anesthesia
during lung surgeries; however, several studies suggest that both VAAs and Propofol inhibit the
protective effects of hypoxic pulmonary vasoconstriction in a dose-dependent manner.8 When
medications inhibit HPV during one-lung ventilation, the pulmonary vasculature allows more
blood flow towards the hypoxic surgical lung. This blood supply misses out on the opportunity to
pick up oxygen from ventilated alveoli and participate in gas exchange, thus reducing the overall
oxygen concentration within the systemic circulation. The pressing need to preserve HPV,
improve intraoperative oxygenation, and provide adequate pain control to improve patient
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outcomes warrants the search for an anesthetic modality free from the limitations of current
anesthetic practices.
The use of Dexmedetomidine (DEX) as part of a balanced anesthetic technique has
gained popularity recently because of the drug's ability to provide sedation and anxiolysis without
depressing respiratory drive.9 While the effects of alpha 2 agonists on heart rate and blood
pressure are well known, research detailing DEX’s impact on the pulmonary vasculature is scarce
and has produced variable results.8 Animal studies propose that Dexmedetomidine may provide
bronchoprotective effects and decrease histamine-induced bronchoconstriction; however, a clear
gap in knowledge exists as to how these results may translate into clinical practice.10
Dexmedetomidine is FDA approved for short-term sedation with mechanical ventilation
or for sedation of non-intubated patients during surgical procedures.11 DEX is valuable as an
anesthetic adjunct, yet it is still underutilized in many clinical settings. The findings of the
aforementioned animal studies have sparked recent interest in evaluating Dexmedetomidine’s
mechanism of action on the inflammatory response of the lungs seen during stressful or hypoxic
conditions, such as those encountered during one-lung ventilation. A handful of studies have
explored whether Dexmedetomidine is responsible for preserving HPV during one-lung
ventilation or if DEX’s bronchoprotective effects only occur due to anesthesia sparing effects of
the primary agent. Currently, there is a lack of evidence-based guidelines, quality improvement
plans, or hospital-based protocols utilizing this application of Dexmedetomidine; therefore, this
scholarly project seeks to evaluate current literature regarding the relationship between
Dexmedetomidine and pulmonary oxygenation during lung surgery and measure the willingness
of anesthesia providers to implement evidence-based practice change based upon our literature
review findings.
Objectives of Literature Review
Developing a clinical question to focus research is an essential component of conducting
a literature review. The PICO mnemonic often used in evidence-based medicine is helpful to
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guide literature reviews and focuses the scope of research on including a specific population (P),
intervention (I), comparison (C), and outcome of interest (O).12 This literature review focuses on
investigating whether the coadministration of Dexmedetomidine (I) in patients undergoing onelung ventilation for lung surgeries (P) will improve oxygenation (O) in comparison to patients
who receive only Propofol or VAAs for anesthetic maintenance. This literature review will then
be utilized to create an educational module for anesthesia providers with the intent of delivering
helpful information to influence the incorporation of evidence-based research into the plan of care
for patients undergoing one-lung ventilation during thoracic lung surgeries. A pre-test post-test
designed implementation strategy utilizing Qualtrics surveys will be executed to determine the
effectiveness of the educational module.

METHODOLOGY OF LITERATURE REVIEW
Search Strategy
A search of the CINAHL, MEDLINE/Proquest, and Embase electronic databases was
conducted to capture a comprehensive view of current evidence regarding the administration of
Dexmedetomidine during one-lung ventilation. Key search terms were identified to build the
search phrase (“one-lung ventilation” OR “lung isolation” OR “single lung ventilation” OR
“hypoxic pulmonary vasoconstriction” OR “thorac*”) AND (“Precedex” OR
“Dexmedetomidine”), which was utilized in all three databases. The Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram was then implemented to
facilitate screening and critically appraise each article utilized in the review.
Study Selection and Screening of Evidence
Appendix A illustrates that the CINAHL database initially yielded 54 results from the
search phrase mentioned above. Filters were applied to screen results to academic journal articles
written in English and published after 1999, when Dexmedetomidine first gained FDA
approval.11 After filters were applied, 52 articles were available for appraisal. The Medline
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database yielded 375 results initially, but after filters were applied to screen results to peerreviewed journals, written in English and published between 1999 and 2020, only 109 articles in
the MEDLINE/Proquest database remain available for appraisal. Lastly, Embase retrieved 630
results, with 336 remaining after screening for journal articles in English with publication dates
between 1999 and 2020. A total of 497 articles resulted from all three databases, and after
duplicates were removed, 428 articles remained for appraisal.
Titles and abstracts of the remaining article were reviewed for relevance to the
population, intervention, comparison, and outcomes of interest for this project. A total of 413
articles were excluded based on the inclusion/exclusion criteria detailed in Appendix B, leaving
15 articles for full-text review. After full-text review of the 15 remaining articles, two were
excluded for data sections written in languages other than English, three were rejected for having
non-human participants, and three were excluded because they did not contain relevant
comparisons. Seven articles remained and therefore were utilized for analysis of the clinical
problem and data comparison. A PRISMA diagram (Appendix D) illustrates the article selection
process, while the synthesis matrix (Appendix C) helps to categorize the data that was collected
and identify the quality of articles chosen, based upon the Johns Hopkins Evidence Level and
Quality Guide.

RESULTS OF LITERATURE REVIEW
Oxygenation Levels
Six out of the seven articles reviewed reported higher oxygenation measurements
amongst the Dexmedetomidine group than their control.13-18 Four studies demonstrated that the
differences in oxygenation levels between groups were statistically significant, suggesting higher
oxygenation due to Dexmedetomidine administration.14,15,17,18 One article observed a reduction in
arterial oxygenation (PaO2) amongst the DEX group in comparison to the control, although this
result was not statistically significant.16
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Timing of Effects
Two studies measured arterial blood gas values every 10 minutes after the initiation of
one-lung ventilation.17,19 The first study suggested that the 30-minute mark may be a pivotal
moment for mediator release during OLV, as the most significant changes in PaO2 and
pulmonary shunt fraction (Qs/Qt) were observed at this time mark.17 This same study also
reported that Dexmedetomidine administration was associated with a statistically significant
decrease in pulmonary shunting across all time intervals, indicating that Dexmedetomidine plays
a beneficial role in reducing shunting after the initiation of OLV.17 Although not statistically
significant, patients in the second study, receiving 0.5mcg/kg/hr of Dexmedetomidine, showed
persistent improvements in PaO2 from 20-50 minutes after OLV compared to the other groups.19
Two other studies, which recorded ABGs at baseline, 30 min, and 60 min after the initiation of
OLV, reported improvements in oxygenation amongst the dexmedetomidine group at both the 30
and 60 minute mark.15,18 The findings from these four studies demonstrate that the most
significant effects of Dexmedetomidine are observed around the same time that hypoxic
pulmonary vasoconstriction is initiated, thus signifying that DEX may play a role in the
preservation or augmentation of HPV.
Dexmedetomidine and Inhalational Anesthetics
Five of the seven studies included in the literature review tested the effects of
Dexmedetomidine coadministration with volatile anesthetic agents by comparing a DEX infusion
to a control group receiving saline.13,14,16-18 Four of these five studies utilizing inhalational
anesthetics observed improvements in oxygenation as a result of Dexmedetomidine infusion.
13,14,17,18

Two of the studies, one utilizing Desflurane and the other using Isoflurane, suggest that

the improvement in oxygenation amongst the DEX group might be due to an anesthetic-sparring
effect.13,16 The authors speculate that because volatile anesthetic agents are known to inhibit
hypoxic pulmonary vasoconstriction, the coadministration of Dexmedetomidine allowed a
reduction in the total concentration of VAAs administered and thus prevented the adverse effects
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of inhaled anesthetics on HPV.13,16 One study, maintaining anesthesia with Sevoflurane, reported
that there was no significant decrease in Sevoflurane concentration administered between the
Dexmedetomidine and control group; therefore, the improvement in oxygenation seen in the DEX
group must be related to the inherent mechanisms of Dexmedetomidine and not due to an
anesthetic-sparing effect.18 A study utilizing Isoflurane and measuring levels of oxidative species
and nitric oxide throughout Dexmedetomidine administration in OLV also suggests that DEX has
an inherent anti-inflammatory property that protects pulmonary functioning, improves
oxygenation, and maintains hypoxic pulmonary vasoconstriction.17
Dexmedetomidine and Propofol
In this review of current literature, two studies compared the effects of Dexmedetomidine
administration on oxygenation in patients receiving intravenous Propofol as the primary
anesthetic agent.15,19 Both studies observed an improvement in oxygenation in at least one of their
groups receiving Dexmedetomidine, although one study reported the effects were not statistically
significant and only observed in the group receiving an intermediate dose (0.5mcg/kg/hr) of
Dexmedetomidine.19 The authors of the same study proposed that Dexmedetomidine infusion did
not significantly decrease the amount of Propofol needed to maintain adequate depth of
anesthesia, thus the mechanism of Dexmedetomidine’s improvements in oxygenation is not
related to an anesthesia-sparing effect.19
The second article reviewed involved a novel experiment seeking to highlight the
effectiveness of nebulized Dexmedetomidine on oxygenation levels and measurements of
pulmonary compliance during OLV.15 This article was included in the review of current literature
despite the nebulized route of administration of Dexmedetomidine because research regarding
dexmedetomidine and propofol coadministration in the setting of OLV for thoracic surgeries is
noticeably limited. In this study, nebulized Dexmedetomidine resulted in statistically significant
improvements in oxygenation, shunting, and lung compliance during OLV compared to the
control group, which was observed amongst all Dexmedetomidine dosages (0.5mcg/kg-
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2mcg/kg).15 Despite the administration of nebulized Dexmedetomidine decreasing propofol
requirements, the authors hypothesize that the dexmedetomidine groups’ improvement in
oxygenation and pulmonary mechanics is related to both an attenuation of pulmonary
inflammatory factors and reduction of propofol dose administered.15
Dose-Dependent Effects
Only two studies in this review explicitly tested for a dose-dependent relationship
between Dexmedetomidine and the drug’s effects on oxygenation.15,19 One study, utilizing
nebulized Dexmedetomidine, found doses of 0.5mcg/kg, 1mcg/kg, and 2mcg/kg to produce
statistically significant improvements in oxygenation and pulmonary shunting in comparison to a
normal saline placebo.15 A second study revealed that dexmedetomidine increases PaO2 after a
loading dose of 1mcg/kg IV and continuous infusion of 0.5mcg/kg/hour, but not with continuous
infusions of 0.3mcg/kg/hour and 0.7mcg/kg/hour.19 Improvements in oxygenation observed in
this second study were not statistically significant,19 and it should be noted that the two studies in
this review that explicitly tested for dose-dependent relationships were also the two studies that
utilized Propofol as the primary anesthetic agent.
All studies with inhalational anesthetic agents that reported improvement of oxygenation
following DEX infusion utilized a bolus of 1mcg/kg over 10 minutes, followed by a continuous
rate of 0.5mcg/mg/hour or greater.13-15,17,18 The only study that reported decreased PaO2 amongst
the DEX group compared to the control administered Dexmedetomidine at a continuous rate of
0.3mcg/kg/hr.16 These results amongst both the Propofol and volatile anesthetic studies suggest a
dose-dependent relationship exists and a loading dose of 1mcg/kg of Dexmedetomidine over 10
minutes followed by an infusion of at least 0.5mcg/kg/hr should be administered to produce
improvements in oxygenation.
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DISCUSSION OF LITERATURE REVIEW
Summary of Evidence
Kernan et al. observed an improved in PaO2/FiO2 ratio, a measurement of oxygenation,
when Dexmedetomidine was co-administered with Isoflurane, but because the results were not
statistically significant, the authors hypothesized that the reason for this improvement might be
due to Dexmedetomidine’s ability to limit the dose of Isoflurane rather than a mechanism
produced by Dexmedetomidine itself.13 Volatile anesthetic agents are known to inhibit hypoxic
pulmonary vasoconstriction; thus, reducing the total concentration of these agents could
theoretically be the mechanism for improvements in oxygenation and pulmonary shunting.13 Xia
et al.’s original study in 2013 showed that Dexmedetomidine administered with a loading dose of
1mcg/kg over 10 minutes and maintained with a continuous infusion of 0.7mcg/kg/hour produced
statistically significant reductions in pulmonary shunting (Qs/Qt%) and improvements in arterial
oxygen pressure (PaO2).14 The measurement of both oxygenation and shunt fraction allowed the
authors to establish that Dexmedetomidine does indeed play a role in preserving hypoxic
pulmonary vasoconstriction and reducing pulmonary shunting. However, only a hypothesis of the
mechanism was described.
A follow-up study by Xia et al. in 2015 expanded on the 2013 research and measured
levels of nitric oxide (NO) and reactive oxygen species superoxide dismutase (SOD) and
malondialdehyde (MDA), in addition to PaO2 and shunt fraction, in an attempt to highlight
Dexmedetomidine’s impact on oxidative stress and pulmonary vasodilation during one-lung
ventilation.17 Xia and colleagues found a significant decrease in MDA, an inflammatory factor
associated with oxidative stress, and a significant increase in nitric oxide, a potent vasodilator.17
These findings were able to confirm that the improvement in oxygenation seen with
Dexmedetomidine infusion during OLV is related to the drug’s ability to reduce oxidative stress,
improve hypoxic pulmonary vasoconstriction, decrease shunt fraction, and increase PaO2; not
just as a byproduct of decreased Isoflurane concentration.17
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Finally, a study by Lee and colleagues confirmed the benefits of Dexmedetomidine
coadministration with Sevoflurane during OLV, as their research demonstrated significant
increases in both oxygenation and airway compliance amongst the DEX group.18 These results
endorse that there are inherent mechanisms of Dexmedetomidine responsible for improvements in
oxygenation during one-lung ventilation beyond the simpler anesthetic-sparing effect theory
speculated by other studies.18
Limitations of Literature Review
As with most scientific research, several limitations exist within this review of current
literature. The primary limitation of this review is the exclusion of articles written in languages
other than English, such as Chinese and Arabic, based on the primary investigator’s language of
origin. The limited number of English articles combined with the inability of the research team to
translate articles written in different languages into valid data points for this literature review
means that potentially valuable findings may have been missed. Additionally, this literature
review only included articles that were peer-reviewed or published within academic journals.
This lack of consideration for grey literature and expert opinions potentially exposes our findings
to publication bias.
A second limitation of our research involves the variability of DEX dosing amongst the
studies included. This literature review only found two studies that explored the dose-dependent
relationship of Dexmedetomidine’s effects on oxygenation, and from these two studies, only one
study found a statistically significant result.15 The two studies that explored a dose-dependent
relationship used Propofol as their control anesthetics; therefore, no statistically significant data
was uncovered regarding DEX dosing and inhalational anesthetics, despite the majority of articles
utilizing inhalational anesthetic agents as their primary agent. Future research is needed to
establish dosing recommendations for Dexmedetomidine coadministration during one-lung
ventilation that will elicit the drug’s beneficial effects.
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The third limitation of this literature review lies within the participant selection and
methodology of the included studies. All seven articles included in this review are single-center
randomized control trials.13-19 Despite RCTs being Level 1 evidence on the Johns Hopkins
Evidence Level and Quality Guide, multicentered studies conducted by multiple groups of
researchers might have produced greater generalizability of results and diversity in the sample
population. Four of the seven studies included ASA I and II participants.14,15,17,19 Two of the seven
included up to ASA III participants16,18 and no studies allowed ASA IV. Five studies explicitly
excluded participants with severe underlying comorbidities such as heart, liver, or kidney disease
and substance abuse or psychiatric disorders.14-17,19 Only one study focused on patients with a
diagnosis of COPD, which is commonly found in patients with smoking history or lung cancer,
and who are likely to need thoracotomies.18 Although 419 participants were included amongst the
seven studies, the lack of research on patients with significant comorbidities that are reflective of
the general population requiring thoracic lung surgery may limit the generalizability of these
findings or have artificially overestimated the beneficial results.
Recommendations for Future Research
Future research regarding the effects of Dexmedetomidine on oxygenation during onelung ventilation is certainly needed. The mechanism of how DEX improves oxygenation during
OLV is under-researched and often attributed to an anesthetic-sparing effect of the primary
agent.13,16 Only one of the seven studies reviewed proposed a direct biochemical mechanism of
action for the results seen within their study.17 Two of the seven studies concluded that
Dexmedetomidine must have an inherent ability to improve oxygenation separate from
anesthetic-sparing effects but were unable to suggest how this is accomplished.15,18 A more
detailed investigation into the dosing of Dexmedetomidine to achieve desired improvements in
oxygenation might also be explored, especially when co-administered with inhalational
anesthetics.
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Limitations of this current review need to be addressed in future research to produce
more generalizable results for the typical population that requires one-lung ventilation and lung
surgery. Patients with significant cardiovascular, pulmonary, and renal comorbidities may receive
the most benefit from strategies to improve intraoperative oxygenation and therefore should be
involved in future research studies. Barriers to future literature reviews, such as language, can be
reduced by including researchers from multilingual backgrounds within the research team.
METHODOLOGY OF QUALITY IMPROVEMENT
Setting and Recruitment
The setting for the implementation of this educational module was within the Broward
Health system, specifically amongst the employees of the Anesco group, which provides
anesthesia services to patients in Broward County, Florida. Broward Health Medical Center is a
716 bed, Level 1 trauma facility and the largest medical center in Broward County, offering
virtually every medical and surgical specialty. MD and CRNA anesthesia providers at this
location frequently care for high acuity patients, classified as ASA 3 and 4, and frequently utilize
one-lung ventilation during pulmonary surgeries; therefore, they are an appropriate target
audience for this evidence-based educational module. IRB approval from both Broward Health
and Florida International University was obtained for the implementation of this module.
Participants were recruited through email lists procured with permission from the Anesco
anesthesia group leadership team. Recruitment emails were delivered to CRNA providers
containing a brief description of the benefit of the educational module, requirements for their
participation, and the anticipated time commitment. Incorporating this information into the initial
recruitment letter was designed to foster participation by addressing potential barriers. An
anonymous Qualtrics link to the pre-test, post-test, and the educational module was also included
in the recruitment email, allowing participants’ information to remain confidential at all times as
no personally identifiable information was collected, in agreement with the IRB-approved
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protocol. Participants were allowed three weeks to complete the educational session and the
pre/post-test knowledge surveys.
Intervention
An educational module summarizing the findings from our review of current literature
regarding the use of Dexmedetomidine to improve oxygenation during one-lung ventilation was
created utilizing Microsoft PowerPoint and published with voice-over content. A quasiexperimental pretest-posttest survey design was then incorporated using the Qualtrics online
survey platform to administer a questionnaire to a convenience sample of CRNAs working within
the Broward Health system via email. CRNAs were given a pre-test survey to assess baseline
knowledge of Dexmedetomidine, variables affecting hypoxic pulmonary vasoconstriction, and
the frequency of which they utilize Dexmedetomidine for thoracic lung surgeries. Once the pretest was completed, the CRNAs were instructed to review an educational PowerPoint presentation
disseminating the beneficial findings of a current literature review on Dexmedetomidine’s role in
improving oxygenation during lung surgeries requiring one-lung ventilation. CRNAs were then
asked to complete the post-test Qualtrics questionnaire. A control group was not established for
this study design, and the educational module represents the intervention that was implemented to
manipulate CRNA’s knowledge of Dexmedetomidine’s ability to alter oxygenation during
hypoxic conditions.
Data Collection
The Qualtrics platform was used for the collection of data from the pre/post-test
questionnaires. Qualtrics data was then downloaded onto a password-protected laptop, where data
was manually compared to identify if a change in the knowledge or behaviors of CRNAs
occurred after watching the educational module. The data was then input into Microsoft Excel to
develop graphic comparisons of the pre and post-test results so that generalizations and
comparisons could be visualized.
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Protection of Human Subjects
Institutional Review Board (IRB) approval was obtained from Florida International
University and the Broward Health IRB for this study protocol as a means to protect the rights
and safety of all participants (Appendices E and F). An informational message describing the
study and the risks and benefits of participation was presented to all Broward Health CRNAs
before launching the questionnaires and modules. Participation in the educational module was
completely voluntary, and subjects were notified that they were free to withdraw from
participation at any time. A randomized numerical digit was provided to each participant at the
beginning of the survey to protect the anonymity of participants throughout the implementation of
the educational module. The results of all questionnaires were stored securely on a passwordprotected laptop. Only the principal investigator had access to these responses, thus ensuring
security, anonymity, and data privacy. Lastly, the authors of the study had no financial interests to
disclose pertaining to the development or implementation of the study
RESULTS OF QUALITY IMPROVEMENT
Participant Demographics
A total of five participants completed the evidence based-educational module by viewing
the presented content and answering the pre-test and post-test surveys. The participant
demographics are displayed in Table 1 below. The majority of the participants were female (n=3,
60%), as opposed to male (n=2, 40%), with most participants identifying their age as between 3049 years old (n=3, 60%). Other participants reported age groups 18-29 (n=1, 20%) and 50-69
(n=1, 20%). There were no participants reporting age as 70 years or greater (n=0, 0%). A diverse
population of participants was observed, with Hispanic (n=2, 40%) being the largest lineage of
respondents, followed by Caucasian (n=1, 20%), African American (n=1, 20%), and Other (n=1,
0%). No participants claimed Asian ethnicity (n=0, 0%). Lastly, participant level of experience
was assessed by asking “How many years have you been administering anesthesia?”, which
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produced the following results: 0 - 2 years (n=2, 40%), 3 - 5 years (n=1, 20%), 6 - 10 years (n=1,
20%), and 10+ years (n=1, 20%).
Table 1. Pre-Test/Post-Test Participant Demographics
Demographics

N (%)

Total Participants

5 (100%)

Gender
Male

2 (40%)

Female

3 (60%)

Age
18-29

1 (20%)

30-49

3 (60%)

50-69

1 (20%)

70+

0 (0%)

Ethnicity
Hispanic

2 (40%)

Caucasian

1 (20%)

African American

1 (20%)

Asian

0 (0%)

Other

1 (20%)

Experience
0-2yrs

2 (40%)

3-5yrs

1 (20%)

6-10yrs

1 (20%)

10+yrs

1 (20%)

Pre-Test Knowledge and Opinions
Current knowledge of Dexmedetomidine, HPV, and anesthetic management of lung
surgeries requiring one-lung ventilation was assessed by asking participants to answer a pre-test
survey. The complete pre and post-test survey can be found in Appendix G, while a summary of
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the number of the participants who answered correctly is displayed in Table 2. The indications for
OLV (n=5, 100%), physiology of HPV (n=5, 100%), and mechanisms of action for
Dexmedetomidine (n=5, 100%) were well understood at baseline as evidenced by all participants
answering correctly. The mechanism of how DEX is able to improve oxygenation during OLV,
however, was poorly understood at baseline amongst participants (n=2, 40%), which indicated an
opportunity for learning to occur. Operative complications associated with OLV (n=3, 60%),
significant risk factors affecting recovery after OLV (n=4, 80%), and anesthetic agents associated
with HPV inhibition (n=3, 60%) were correctly reported by only a fraction of the participants
prior to viewing the module, signifying a need for education. Pre-test willingness to implement
the coadministration of Dexmedetomidine during pulmonary surgeries requiring one-lung
ventilation was as follows: somewhat unlikely (n=1, 20%), somewhat likely (n=2, 40%), and very
likely (n=2, 40%).
Table 2. Difference in Pre- and Post- Test Knowledge
Questions

Pre-

Post-

Difference

Test

Test

1. One lung ventilation (OLV) is required during many ____
procedures to optimize surgical conditions:
2. What are the two most significant factors that delay
recovery after OLV?
3. OLV is associated with which intraoperative complications?

100%

100%

0

80%

100%

20%

60%

60%

0

4. Hypoxic pulmonary vasoconstriction (HPV) is an adaptive
mechanism unique to the pulmonary vasculature that allows
for:
5. Which anesthetic agent is known to inhibit HPV when
administered in high concentrations?
6. Dexmedetomidine is an:

100%

100%

0

60%

80%

20%

100%

100%

0

7. The coadministration of Dexmedetomidine with volatile
anesthetic agents or Propofol during OLV can:
8. The proposed mechanism through which Dexmedetomidine
improves oxygenation and preserves HPV during one-lung
ventilation is by:

100%

100%

0

40%

80%

40%
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Post-Test Knowledge and Opinions
As expected, more participants were able to correctly identify the mechanisms through
which DEX improves oxygenation and preserves HPV during OLV after viewing the educational
intervention (n=4, 80%) than at baseline (n=2, 40%). A greater number of participants were also
able to identify risk factors that delay recovery after OLV (n=5, 100%) and recall anesthetic
agents associated with HPV inhibition when administered in high concentrations (n=4, 80%) on
the post-test survey. These findings suggest that learning occurred after the information was
presented within the educational module. Additionally, the number of providers that reported they
were “very likely” (n=4, 80%) to adopt the evidence-based intervention after viewing the
presentation doubled from pre-test (n=2, 40%), suggesting that a meaningful clinical practice
change may occur as a result of the teaching. Figure 1, below, further illustrates these described
changes in provider willingness to utilize the coadministration of Dexmedetomidine in future
pulmonary surgeries requiring one-lung ventilation.
Figure 1. Difference in Pre- and Post- Test Willingness to Adopt Intervention
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DISCUSSION OF QUALITY IMPROVEMENT
Implications for Advanced Practice Nursing
As the number of intrathoracic procedures for the diagnosis and treatment of lung cancer
continues to rise, the need for continued research and evidence-based practice will continue to
follow. The utilization of one-lung ventilation for optimal operating conditions produces a highly
abnormal physiological state which is often not tolerated for long periods amongst healthy
individuals, let alone patients suffering from years of smoking and pulmonary pathologies
associated with lung cancer, such as COPD or emphysema. Advanced practice nurses involved
with the management of anesthesia for these procedures must be acutely aware of all possible
interventions available to optimize pulmonary function and recovery.
The outcomes of this review of current literature support adopting Dexmedetomidine
coadministration with either Propofol or volatile anesthetic intraoperatively to preserve hypoxic
pulmonary ventilatory mechanisms, as well as improve oxygenation and facilitate postoperative
recovery. The results of our pre and post-test questionnaire suggest that learning did indeed occur
via this virtual presentation and that this teaching style may be utilized to implement clinical
practice changes in the future. The willingness of providers to implement the evidence-based
practice changes addressed within this presentation doubled between the pre and post-test
questionnaire (Figure 1), suggesting an opportunity for organizational practice change moving
forward.
Limitations
Limitations of this project include the small sample size and difficulty with participant
recruitment. Despite the survey deployment to the entire email list obtained from the target
anesthesia group, most invitations to participate in the survey remained unused. Only five
participants contributed to the findings presented in this project; therefore, our results are
underpowered and unable to ensure reliability or generalizability. In order to achieve greater
participation in the future, multiple recruitment avenues should be attempted. Unfortunately, face-
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to-face reminders and other in person prompts to increase participant recruitment were unable to
be utilized due to COVID-19 social distancing mandates imposed at the time of this educational
module’s distribution.
CONCLUSION
Four out of seven studies in the literature review observed a statistically significant
improvement in oxygenation amongst patients receiving Dexmedetomidine during one-lung
ventilation;14,15,17,18 therefore, the coadministration of Dexmedetomidine may be considered an
appropriate intervention to reduce the degree of hypoxia seen in lung surgeries. If maintaining
oxygenation and preventing inflammatory changes in the lungs during surgery can lead to
improved postoperative outcomes and reduce hospital length of stay, then it becomes even more
imperative for anesthesia providers to learn about the benefits of Dexmedetomidine
coadministration. The number of research articles available on this topic, however, remains
limited; therefore, further research into the mechanism of action through which
Dexmedetomidine might preserve hypoxic pulmonary vasoconstriction is certainly needed. As
the prevalence of lung surgeries continues to rise, research and education regarding the anesthetic
management of these complicated patients must also persist.
This educational module demonstrated the ability to facilitate learning virtually as
evidenced by improved scores in the pre and post-test surveys. This educational module also
demonstrated the ability to influence anesthesia provider willingness to implement evidencebased practice changes; thus, signifying that virtual learning, despite recruitment concerns, retains
the potential to ignite meaningful clinical practice change. Our project supports the continued
utilization of virtual learning platforms because of their potential to bridge the research to practice
gap and quickly disseminate best evidence-based practices to local, national, and global
audiences.
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APPENDIX A: DATABASE SEARCH
Table 1. Database Search
Database
CINAHL

Keywords & concepts

Filters applied

(“one lung ventilation” OR “lung

Initial # of Results: 54

isolation” OR “single lung ventilation”

Filters Applied:

OR “hypoxic pulmonary

•

Academic Journals

vasoconstriction” OR “thorac*”) AND

•

English Language

(“Precedex” OR “Dexmedetomidine”)

•

Published 1999-2020

# of Results after filters: 52
MEDLINE

(“one lung ventilation” OR “lung

Initial results: 375

(ProQuest)

isolation” OR “single lung ventilation”

Filters Applied:

OR “hypoxic pulmonary

•

Peer reviewed

vasoconstriction” OR “thorac*”) AND

•

English Language

(“Precedex” OR “Dexmedetomidine”)

•

Publication date: 19992020

Results after filters: 109
Embase

(“one lung ventilation” OR “lung

Initial results: 630

isolation” OR “single lung ventilation”

Filters Applied:

OR “hypoxic pulmonary

•

vasoconstriction” OR “thorac*”) AND
(“Precedex” OR “Dexmedetomidine”)

Academic Journal
Articles

•

English Language

•

Publication date: 19992020

Results after filters: 336
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APPENDIX B. INCLUSION AND EXCLUSION CRITERIA
Table 2. Inclusion and Exclusion Criteria
Inclusion

Exclusion

Population:
• Adult human participants
Type of Procedures:
• Thoracic surgeries involving the
lungs
Anesthetic Management:
• One lung ventilation under general
anesthesia
Intervention/Comparison
• Dexmedetomidine in combination
with VAAs or Propofol compared to
control group receiving only VAAs or
Propofol and no dexmedetomidine
Primary Outcomes
• Direct measurements of oxygenation
o (ex: ABGs, PaO2, SpO2,
PaO2/FiO2 ratio)
• Measurement of HPV and lung
compliance
o Shunt fraction (Qs/Qt)
o Pulmonary compliance (Cdyn
ml/cmH2O)
o Serum concn of inflammatory
mediators
Type of Study:
• English Language
• Randomized placebo-controlled trials
• Publication date 1999-Present
• Published in a scientific journal

Population:
• Participants <18 years old
• Animal studies
Types of Procedures:
• Non-surgical procedures (ex.
imaging studies, biopsies)
• Thoracic surgeries of non-lung
origin (esophageal repair,
mediastinal mass, minimally
invasive cardiac procedures etc.)
Anesthetic Management
• Non general anesthesia modalities
(i.e., regional anesthesia, MAC,
etc.)
• Ventilation modalities other than
one lung ventilation (ex. two lung
ventilation, spontaneous
ventilation, etc.)
Intervention/Comparisons
• Studies that did not include the use
of Dexmedetomidine
• Studies that did not include the use
of Propofol or VAAs
• Studies without control group
receiving only VAAs or Propofol
Primary Outcomes
• Any other outcomes besides
measurements of oxygenation,
lung compliance, and inflammation
Type of Study
• Non-English body of text
• Publications before 1999
• Articles without titles or abstracts,
or non-scientific journals
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APPENDIX C. LITERATURE MATRIX
Citation and
Theme of
the article

Design/Metho
d

Kernan et al.,
2011

Prospective,
Randomized,
double-blinded
trial

Key Concept:
DEX
improved
PaO2 &
decreased
Desflurane
req.

Sample/Setting

•

•
Level 1
Evidence

Strength:
Randomization,
doubleblinding
•
Weakness:
Small sample
size, did not
reach statistical
significance

Tertiary care,
Universitybased
hospital
19 adult
patients
undergoing
thoracic
surgery
requiring
OLV (9
DEX, 10
Placebo)
No
differences in
demographic
al data
between
groups
reported

Major
Variables
Studied and
Their
Definitions
• During
inhalational
anesthesia
with
Desflurane,
patients
were
randomized
to either
receive
Dexmedeto
midine
(0.3mcg/kg
bolus
followed by
0.3mcg/kg/h
r infusion)
or saline
placebo.
• PaO2/FiO2
ratio
measured

Measurement
And Data
Analysis
•

Three
arterial
blood gas
samples to
examine
levels of
oxygenation
(1) 10 min
after
anesthetic
induction
during two
lung
ventilation,
(2) after 10
min of
OLV, and
(3) 15
minutes
after study
drug bolus
while
continuous
infusion
being
administere
d

Findings

ABG #1 - Two
lung ventilation
• DEX group
PaO2/FiO2
ratio 387 +/124
• Placebo
PaO2/FiO2
ratio 363 +/107
ABG #2- One
lung ventilation
• DEX group
PaO2/FiO2
ratio 194 +/99
• Placebo
PaO2/FiO2
ratio 188 +/70
ABG #3- One
Lung ventilation
with DEX vs
placebo
administration
• DEX group
PaO2/FiO2

Results/ Conclusions

•

•

•

•

No difference in
oxygenation was seen
between the groups during
two-lung ventilation
(ABG#1) and one lung
ventilation prior to
administrations of
Dexmedetomidine (ABG
#2).
Although it did not reach a
statistical significance, level
of oxygenation, expressed as
PaO2/FiO2 ratio, was greater
during one lung ventilation
in patients receiving
dexmedetomidine (188 +/115) compared to the
placebo (135 +/- 80).
With the administration of
DEX, there was a decrease
in the expired concentration
of Desflurane required to
maintain a bispectral index
of 40-60, when compared to
the control group (4.5 ±
0.8% versus 5.1 ± 0.8%)
The improved oxygenation
with Dexmedetomidine may
have resulted from the direct
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•

ratio 188 +/115
Placebo
PaO2/FiO2
ratio 135 +/80

effects of Dexmedetomidine
on HPV or more likely
because of the anesthetic
sparing effects of
Dexmedetomidine, which
allowed for decrease in
concentration of Desflurane,
thus lessening its effects on
HPV.13
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Xia et al.,
2013

Key Concept:
DEX
improves
PaO2 &
decreased
shunting, less
Isoflurane
req.

Randomized
control trial

•

Level 1
Evidence

Strength:
Randomization,
Large sample
size,
Achieved
statical
significance in
multiple data
points,
Exhaustive data
collection
across multiple •
time periods
Weakness:
High # of drop
outs due to
SpO2 or BIS

•

60 ASA I-II
patients aged
18-70 years
old, weighing
43-73kg,
height 151175cm, with
no serious
underlying
heart, lung,
liver, or
kidney
disease
undergoing
OLV during
elective
thoracic
surgery
No statistical
significance
between
demographic
s of groups
10 cases were
withdrawn
from the
study when
SpO2 was
observed
<90% and
OLV was
discontinued,
5 cases were
withdrawn
due to BIS
values

•

•

•

•

All patients
were
randomly
divided into
two groups
30 adults
received
isoflurane +
saline bolus
& drip, 30
adults
received
isoflurane +
DEX (1.0
mcg/kg
bolus over
10 min
followed by
0.7mcg/kg/h
r continuous
infusion)
All patients
received
continuous
infusion
remifentanil
0.1-0.2
mcg/kg/min
and
isoflurane
1.0-2.0%
keeping BIS
value 40-60
PaO2 &
Qs/Qt ratio
measured

•

Five arterial
blood gas
samples
were
collected:
(1) after 15
min of two
lung
ventilation
(TLV-15),
(2) after 10
min OLV
(OLV-10),
(3) after 20
min OLV
(OLV-20),
(4) after 30
min OLV
(OLV-30),
(5) after 40
min OLV
(OLV-40).

ABG #1 TLV15min
• DEX group
PaO2 452+/83.2 mmHg;
QS/QT (%)
12.5 +/- 2.5
• Placebo group
PaO2 460.5+/89.5 mmHg;
QS/QT (%)
11.7 +/- 1.5

•

•

•
ABG #2 OLV10min
• DEX group
PaO2 257.8 +/69.7 mmHg;
QS/QT (%)
30.4 +/- 2.5
• Placebo group
PaO2 225.5 +/89.5 mmHg;
•
QS/QT (%)
38.7 +/- 1.7
ABG #3 OLV20min
• DEX group
PaO2 197.5 +/64.3 mmHg;
QS/QT (%)
24.4 +/- 2.5
• Placebo group •
PaO2 169.2 +/71.3 mmHg;

After the initiation of OLV,
PaO2 starts to decrease
significantly in both groups
(P<0.05) down to a valley at
the 30-minute mark, then
begins to rise at the 40minute mark due to the role
of HPV.
During OLV, PaO2 was
significantly higher in the
DEX group in comparison to
the control group (P<0.05).
Qs/QT, a measure of
pulmonary shunt describing
the percentage of blood that
reaches the left side of the
heart without picking up
oxygen, was significantly
lower in the DEX group than
the control group across all
intervals during OLV
(P<0.05).
Qs/QT ratio is typically 25% during normal breathing,
about 10% after general
anesthesia, and 40-50%
during OLV,14 but with the
infusion of DEX, maximum
Qs/QT ratio with OLV was
30.4 +/- 2.5 % at the 10 min
mark and significantly lower
than control group 38.7+/1.7% (P<0.05).
This study confirms that
intravenous
Dexmedetomidine along
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outside of the
control range

QS/QT (%)
31.5 +/- 2.0

ABG #4 OLV30min
• DEX group
PaO2 182.6 +/72.2 mmHg;
QS/QT (%)
24.5 +/- 3.5
• Placebo group
PaO2 152.3 +/69.4 mmHg;
QS/QT (%)
30.7 +/- 2.8
ABG #5 OLV
40min
• DEX group
PaO2 205+/83.2 mmHg;
QS/QT (%)
23.1 +/- 2.5
• Placebo group
PaO2 170.8 +/89.5 mmHg;
QS/QT (%)
27.5 +/- 1.9

with isoflurane inhalation
during OLV can
significantly reduce the drop
in arterial oxygen pressure,
reduce the degree of
increased intrapulmonary
shunting, and reduce
isoflurane dose, while also
confirming safety and
feasibility of DEX infusion
in OLV.
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Xu B, Gao H, Randomized
•
Li D, Hu C,
control trial
Yang J., 2019
•
Level 1
Evidence
Key Concept:
Neb DEX,
improves
Strength:
PaO2,
Randomization,
improves
Measurement
pulmonary
of dynamic
compliance,
compliance,
decreases
Achieved
shunting, and statistical
decreased
significance
Propofol req.
Weakness:
Feasibility of
nebulized DEX

•

•

Hospital•
based study
128 patients,
ASA I &II,
aged 2080yrs old,
height 150180cm, with
no previous
allergic rxn
to DEX and
no serious
cardiovascula
r, liver,
kidney,
neuropsychia
tric, or drug
dependence
disorders
undergoing
•
elective
thoracoscopic
surgery
Randomly
divided into 4
groups:
Placebo/Salin
e
Dex
0.5mcg/kg
Dex 1mcg/kg
Dex 2mcg/kg
No
statistically
significant
differences

After
bronchial
intubation
but prior to
initiation of
OLV,
patients
received
different
doses of
nebulized
DEX in 5
mL
(0.5mcg/kg,
1mcg/kg,
2mcg/kg) or
5mL of
0.9% saline
placebo.
OLV was
initiated 15
min after
bronchial
intubation,
and
anesthesia
was
maintained
with IV
infusion of
Propofol
and
cisatricuriu
m, titrating
propofol
infusion to

•

•

Arterial
Blood gas
samples
were taken:
(1) 15 min
after
bronchial
intubation
during two
lung
ventilation
(TLV), after
30 mins (2)
and 60 mins
(3) of OLV,
and (4) 15
min after
reinstitution
of two lung
ventilation
Dynamic
compliance
was also
calculated at
the same
intervals

ABG #1 -TLV
15min
PaO2 (mmHg)
• Placebo431.8 +/- 54.3
Dex 0.5 435.8 +/- 44.1
Dex 1 - 424.4
+/- 38.7
Dex2 - 423 +/53.3
Qs/Qt (%)
• Placebo- 9.9
+/- 2.2
Dex 0.5 - 9.8
+/- 1.2
Dex 1 - 9.4 +/2.0
Dex2 - 9.7 +/2.3
Cdyn (ml/cmH2O)
• Placebo- 43.4
+/- 7.1
Dex 0.5 - 42.8
+/- 6.0
Dex 1 - 42.2
+/- 5.3
Dex2 - 41.5
+/- 4.3
ABG #2 -OLV
30min
PaO2 (mmHg)

•

•

•

•

This study found that at the
30 and 60-minute OLV
ABG, statistically significant
increases in PaO2 were
observed amongst all DEX
groups in comparison to the
control (P<0.05)
Statistically significant
improvement in dynamic
compliance was also
observed amongst all DEX
dosages (0.5mcg/kg2mcg/kg) at the 30 and 60minute OLV mark (P<0.05).
Statistically significant
reductions in pulmonary
shunting (Qs/Qt) were
observed with 1mck/kg and
2mcg/kg nebulized DEX
groups and the 30 & 60minute OLV interval, in
comparison to the placebo
group.
Nebulized
Dexmedetomidine improved
oxygenation not only by
reducing intrapulmonary
shunting but by also
improving lung compliance
during OLV. The
administration of nebulized
DEX also decreased
propofol requirements and
avoided significant
hemodynamic instability,
validating the feasibility of
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existed
between
demographic
s of each
group

•

maintain
bispectral
index 40-50,
PaO2, Qs/Qt
ratio, and
dynamic
compliance
(Cdyn)
measured

•

Placebo168.6 +/- 43.6
Dex 0.5 217.9 +/- 43.5
Dex 1 - 242.5
+/- 60.8
Dex2 - 262.7
+/- 53.6
Qs/Qt (%)
• Placebo- 30.4
+/- 2.3
Dex 0.5 - 30.0
+/- 3.0
Dex 1 - 24.6
+/- 2.2
Dex2 - 22.6
+/- 2.5
Cdyn (ml/cmH2O)
• Placebo- 21.0
+/- 2.8
Dex 0.5 - 26.7
+/- 2.4
Dex 1 - 26.4
+/- 2.6
Dex2 - 26.9
+/- 3.2
ABG #3 -OLV
60min
PaO2 (mmHg)
• Placebo178.5 +/- 41.3
Dex 0.5 255.6 +/- 47.0

•

utilizing nebulized DEX to
improve oxygenation during
OLV.
The authors hypothesize
these effects may be related
to an attenuation of local
inflammation factors that
contribute to the hypoxic
vasodilator effect of OLV,
due to DEX’s ability to
reduce pro-inflammatory
factors. Secondly, DEX may
play a direct role in
pulmonary artery mechanics
by impacting
bronchodilation, and also
reducing the requirement of
Propofol, which has shown
to attenuate HPV in a dose
dependent manner, thus
decreasing the dose of
Propofol may lead to the
decrease pulmonary shunt
and improved HPV.15
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Dex 1 - 282.1
+/- 54.6
Dex2 - 298.6
+/- 38.4
Qs/Qt (%)
• Placebo- 27.5
+/- 1.4
Dex 0.5 - 27.2
+/- 2.5
Dex 1 - 22.3
+/- 3.6
Dex2 - 26.2
+/- 2.9
Cdyn (ml/cmH2O)
• Placebo- 19.7
+/- 2.8
Dex 0.5 - 26.2
+/- 2.4
Dex 1 25.5+/- 2.6
Dex2 - 26.2
+/- 2.9
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Asri et al.,
2020
Key
Concepts:
Dex &
Isoflurane No
significant
differences in
PaO2
between
groups

Doubleblinded,
Randomized
control trial

•
•

Level 1
Evidence

Strength:
Randomization,
inclusion of
•
sicker
population
Weakness:
Results conflict
with
discussion, few
data points
achieved
statistical
significance

•

University
funded study
42 patients
ASA I-III
aged 20-60
yrs
undergoing
OLV and
elective
thoracic
surgery
Excluded
participants
with liver or
kidney
dysfunction,
end-stage
COPD,
severe heart
block, or
uncontrolled
HTN
No
significant
difference
identified in
baseline
demographic
s and
hemodynami
c

•

•

•

•

General
anesthesia
provided
with
inhalational
isoflurane;
patients
randomized
into DEX
group
(DISO)
(0.3mcg/kg
DEX bolus
IV over 10
min +
infusion
0.3mcg/kg/h
r) and saline
bolus
(NISO) with
infusion
group
Isoflurane
titrated to
BIS of 4060
Remifentan
yl titrated to
hemodynam
ic stability
PaO2
measured

•

Arterial
Blood gas
sampling
occurred at
10 min after
induction of
anesthesia
but before
OLV (T1),
10 minutes
after starting
OLV (T2),
and after
60min of
OLV (T3)

ABG #1 - 10min
TLV
PaO2
• DISO 172.6
+/- 111
• NISO 176.6
+/- 124
ABG #2 - 10min
OLV
PaO2
• DISO 102.5
+/- 56
• NISO 149.9
+/- 104
ABG #3 - 60min
OLV
• DISO 118.4
+/- 54
• NISO 122.6
+/- 71

•

•

•

Shifting from two lung
ventilation to one lung
ventilation decreased PaO2
in both groups
The reduction in PaO2 in the
dexmedetomidine group was
greater than the control
group, although not
statistically significant.
The authors suggest that the
trivial increase in the PaO2
of the DISO group between
the 10 & 60 min OLV ABGs
could be attributed to DEX
administration lessening the
dose of Isoflurane needed to
maintain adequate depth of
anesthesia, b/c volatile
agents are associated with
inhibition of HPV and
increased intrapulmonary
shunting16
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Key
Concepts:
DEX
improved
PaO2 due to
mediator
release

Randomized
control trial

•

Level 1
evidence
•
Strength:
Randomization,
large sample
size, frequent
intervals of
measurement,
valuable
parameters
measured,
statistical
significance
•
achieved

Weakness:
High # of drop
outs due to
SpO2 or BIS

•

Government
funded,
single
institutionbased study
60 male
patients 4060yrs old,
ASA I &II,
50-73kg,
151-175cm,
undergoing
elective
thoracic
surgery were
included in
this study
Exclusion
criteria
included
kidney
disease, liver
dysfunction,
ischemic
heart disease,
substance
abuse and
neuro or
psychiatric
disorders.
A total of 11
participants
(6 from the
control and 5
from DEX)
group were

•

•

•

•

•

Participants
were
randomized
into two
groups
30 patients
received
DEX
infusion
(1mcg/kg/hr
bolus over
10 min,
followed by
0.7mcg/kg/h
r infusion),
30 patients
received a
similar
volume
normal
saline bolus
over 10 min,
followed by
infusion.
All patients
received
remifentanil
0.1-0.2 mcg/
kg/min gtt
and 1.02.0%
isoflurane
titrated to
BIS 40-60
PaO2 and
Qs/Qt ratio

•

•

•

Arterial
Blood gas
samples
were taken:
(1) after 15
min of two
lung
ventilation
(TLV-15),
(2) after 10
mins of
OLV, (3)
after 20 min
of OLV, (4)
after 30min
of OLV and
(5) after 40
min of OLV
Plasma SOD
and MDA
levels were
collected at
the same
intervals as
ABGs
Serum
Nitric Oxide
concn was
collected at
TLV 15 and
OLV 30

ABG #1 TLV15min
• DEX group
PaO2 457.5+/85.2 mmHg;
QS/QT (%)
11.5 +/- 1.8
• Placebo group
PaO2 461.5+/87.5 mmHg;
QS/QT (%)
12.0 +/- 1.1

•

•

•

ABG #2 OLV10min
• DEX group
PaO2 258.6 +/68.6 mmHg;
•
QS/QT (%)
23.5 +/- 2.9
• Placebo group
PaO2 223.5 +/89.7 mmHg;
QS/QT (%)
28.1 +/- 2.5
•
ABG #3 OLV20min
• DEX group
PaO2 198.5 +/68.3 mmHg;
QS/QT (%)
25.3 +/- 2.3
• Placebo group
PaO2 165.2 +/- •
75.3 mmHg;

Initiation of OLV caused a
significant decrease in PaO2
amongst both groups, lowest
value at 30min mark.
The decrease in PaO2 in the
DEX group was less severe
than the control group
(P<0.05).
Qs/Qt % increased
significantly in both groups
upon the initiation of OLV,
peaking at 30 min, but the
extent of shunting in the
DEX group was significantly
less than the shunting
experienced in the control
group (P<0.05)
This study observed the
largest changes in PaO2 and
Qs/Qt % occurred at the 30
min OLV mark. These
results suggested that the 30
min mark of OLV may be a
key moment for mediator
release.17
At TLV 15, there was no
significant difference in
serum nitric oxide
concentration between the
two groups. After 30 min
OLV, the DEX group had
significantly higher levels of
Nitric Oxide in comparison
to the control group.
These findings support the
authors hypothesis that DEX
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•

excluded
from analysis
because of
bispectral
indexes BIS)
over the goal
value or
SpO2 <90%
No
significant
difference
amongst
demographic
s between
groups

were
measured

QS/QT (%)
30.1 +/- 2.0
ABG #4 OLV30min
• DEX group
PaO2 185.6 +/73.2 mmHg;
QS/QT (%)
27.1 +/- 2.1
• Placebo group
PaO2 151.3 +/68.5 mmHg;
QS/QT (%)
27.1 +/- 2.1
ABG #5 OLV
40min
• DEX group
PaO2 209.6+/85.1 mmHg;
QS/QT (%)
23.5 +/- 2.2
• Placebo group
PaO2 171.6 +/88.9 mmHg;
QS/QT (%)
27.7 +/- 2.0
MDA
TLV 15 min
• DEX 16.9 +/1.7
• Placebo 18.3
+/- 1.7
OLV 30 min

combined with Isoflurane
may inhibit oxidative stress
(MDA), maintain SOD, and
increase Nitric oxide release
more than Isoflurane alone,
thus reducing pulmonary
shunt fraction (Qs/Qt) and
improving oxygenation in
OLV.17
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•
•

DEX 17.5 +/1.2
Placebo 21.0
+/- 1.7

SOD
TLV 15 min
• DEX 1.9 +/0.2
• Placebo 1.9
+/- 0.1
OLV 30 min
• DEX 1.8 +/0.3
• Placebo 1.6+/0.2
NO
TLV 15 min
• DEX 1.9 +/0.3
• Placebo 1.9
+/- 0.4
OLV 30 min
• DEX 2.3 +/0.3
• Placebo 1.8+/0.1
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YL, Ban MG,
Oh YJ, 2016
Key
Concepts:
DEX and
Sevoflurane
in COPD

Randomized,
double-blinded,
placebo control
study

•
•

Level 1
Evidence

Strength:
Large sample
size,
representative
sample
population
Weakness:
Report of
primary
outcome data
in figure format

•

Single
•
university
hospital
Fifty
participants
undergoing
videoassisted
thoracoscopic
surgery who
have
moderate
COPD
•
Men, over
40, ASA II or
III, diagnosis
of moderate
COPD, preop FEV1 5080%

•

Participants
were
randomized
into two
groups, a
DEX and a
placebo/
control
group (total
25
participants
each)
DEX group
receives
loading dose
1mcg/kg
over 10 min,
followed by
0.5mcg/kg/h
r
maintenance
infusion,
control
group
received
same
volume and
rate but with
0.9% saline
Titration of
Sevoflurane
to maintain
adequate
anesthetic
depth of BIS
40-60

•

•

•

Arterial
blood gases
were
collected at
three points
in time: (1)
30 min after
initiation of
OLV, (2) 30
min after
DEX
infusion
during OLV
(DEX-30),
& (3) 60
min after
DEX
infusion
during OLV
(DEX-60)
Primary
outcome
measured
was lung
oxygenation
expressed
via
PaO2/FiO2
ratio
Secondary
outcomes
recorded
were
dynamic
compliance,
peak airway

PaO2/FiO2 ratio
30 min OLV

•

•

DEX-30:
27.9kpa +/5.8
• Control:
22.5kpa +/8.4
60 min OLV
• DEX-60:
28.6kpa +/5.9
• Control:
21.0kpa +/9.9
Peak Airway
Pressure (cmH2O)

•

•

•

•

Baseline OLV
• DEX group22.3 +/- 3.9
•
• Control group22.5 +/- 4.9
30 min
• DEX 30: 18.2
+/-3.2
• Control: 23.0
+/- 4.1
60 min
• DEX 60: 18.2 •
+/-2.7
• Control: 21.7
+/- 4.3

The PaO2/FiO2 ratio was
significantly higher in the
dexmedetomidine group at
the 30- and 60-min mark
(P<0.05).
Interesting to note, the end
tidal concentrations of
Sevoflurane were not
statistically different
between groups
Dynamic compliance was
higher in DEX 30 & DEX
60 group in comparison to
the control group (P<0.05)
Plateau airway pressure was
significantly lower in the
DEX group at the 30- and
60-min marks (P<0.05).
PACU PaO2/FiO2 ration
was significantly higher in
the DEX group than the
control group (p<0.05).
Seven patients in the control
group had episodes of SaO2
less than 95% and
PaO2/FiO2 less than 40kPa
while breathing room air,
eventually resulting in ICU
admission. Only one patient
in the DEX group required
care in the ICU
These authors propose that
since the concentration of
Sevoflurane remained
constant between both
groups in the study,
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•

pressure,
and
hemodynam
ic
parameters.
Respiratory
rate and
PaO2/FiO2
ratio were
also
recorded 20
min into
PACU
recovery

Compliance
(ml/cm H2O)
Baseline OLV
• DEX group19.5 +/- 4.9
• Control group19.2 +/- 5.2
30 min
• DEX 30: 22.5
+/-3.5
• Control: 17.7
+/- 3.4
60 min
• DEX 60: 21.4
+/-4.2
• Control: 18.1
+/- 4.6
PACU
PaO2/FiO2 (kPa)
• DEX: 47.5 +/7.1
• Control: 42.2
+/- 5.9

Dexmedetomidine is
responsible for the
increasing the hypoxic
threshold in the study group,
rather than an inhalational
anesthetic-sparing effect.18
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Key Concept:
Dose
dependent
effect of
DEX
infusion,
DEX and
propofol
infusion for
maintenance
of anesthesia

Randomized
control trial,
double-blinded,
placebo control
study

•

•

Level 1
evidence

Strengths:
Comparison of
different
concentrations
of DEX
Weakness:
Small size of
comparison
groups limits
ability to
achieve
statistical
significance,
data report is
summarized
and displayed
in figure format

•

Urban
academic
tertiary care
hospital
Sixty
participants,
male and
females age
18-80 years
old, ASA I &
II with no
serious heart,
lung liver,
kidney
disorders
undergoing
elective
pulmonary
lobectomy
surgeries

•

•

Included 60 •
participants,
randomized
into 4
groups:
placebo/nor
mal saline
group, low
dose DEX
group
(0.3mcg/kg/
hr)
identified as
DEX3,
intermediate •
dose DEX
group
(0.5mcg/kg/
hr)
identified as
DEX5
group, and
high dose
DEX group
(0.7mck/kg/
hr)
identified as
DEX7 group
After
induction of
anesthesia
and baseline
blood
sampling
was
obtained,

Baseline
•
vitals and
ABGs were
obtained
after
induction of
anesthesia
during two
lung
ventilation,
prior to
DEX
administrati
on.
OLV was
initiated,
DEX and
saline
infusions
were
administere
d, and vitals/
ABGs were
collected at
10-minute
intervals for
an hour, and
after the
operation
was
complete

Although no
statistically
significant
differences in
PaO2 were
noted with
increasing
does of DEX,
patients in the
DEX 5 group
receiving the
intermediate
dose
(0.5mcg/kg/hr
) showed
persistent
improvements
in PaO2 from
20-50 minutes
after OLV in
comparison to
the other
groups.

•

•

•

The authors did not observe
a decreased propofol
requirement with the
administration of DEX,
however the dose of atropine
required to maintain heart
rate significantly increased
with the DEX7 group.
The group that received an
intermittent dose of DEX
(0.5mcg/kg/hr) showed
better PaO2 values than all
other groups between 20 and
50 min of OLV, although
this did not reach a level of
statistical significance.
The authors propose that an
infusion of
Dexmedetomidine does not
reduce propofol
requirements, and that DEX
may have dose dependent
effects on oxygenation in
OLV, but additional studies
with larger sample sizes are
necessary. 19
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•

each DEX
group
received
1mcg/kg
bolus in
10ml of
solution,
administere
d over 10
minutes.
The saline
control
received a
similar
volume of
fluid
Adequate
anesthetic
depth was
defined as
BIS 40-60,
and
maintained
via propofol
titration
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Identification

APPENDIX D. PRISMA FLOW DIAGRAM

Records identified through
database searching
(n = 497)

Additional records identified
through other sources
(n = 0)

Included

Eligibility

Screening

Duplicates removed
(n = 69)

Records screened
(n = 428)

Records excluded
(n =413)

Full-text articles assessed
for eligibility
(n = 15)

Full-text articles excluded,
with reasons
(n = 8)
• Body of articles
written in language
other than English (2)
• Animal participants (3)
• Comparison not
relevant to PICO (3)

Studies included in
qualitative synthesis
(n = 7)
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APPENDIX E. IRB APPROVAL LETTERS

Office of Research Integrity
Research Compliance, MARC 414

MEMORANDUM
To:
CC:

Dr. Yasmine Campbell
Robert Dillon , Valerie Diaz

From:

Maria Melendez-Vargas, MIBA, IRB Coordinator

Date:

April 7, 2021

Protocol Title:

“Administration of Dexmedetomidine in Patients Undergoing One Lung
Ventilation for Thoracic Lung Surgeries to Enhance Oxygenation: An
Evidence-Based Education Module”

The Florida International University Office of Research Integrity has reviewed your research
study for the use of human subjects and deemed it Exempt via the Exempt Review process.
IRB Protocol Exemption #:
TOPAZ Reference #:

IRB-21-0132
110243

IRB Exemption Date:

04/07/21

As a requirement of IRB Exemption you are required to:
1) Submit an IRB Exempt Amendment Form for all proposed additions or changes in the
procedures involving human subjects. All additions and changes must be reviewed and
approved prior to implementation.
2) Promptly submit an IRB Exempt Event Report Form for every serious or unusual or
unanticipated adverse event, problems with the rights or welfare of the human subjects,
and/or deviations from the approved protocol.
3) Submit an IRB Exempt Project Completion Report Form when the study is finished or
discontinued.
Special Conditions: N/A

For further information, you may visit the IRB website at http://research.fiu.edu/irb.

MMV/em
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Broward Health Medical Center
Broward Health Coral Springs
Broward Health Imperial Point
Broward Health North

Institutional Review Board - Human Research Protections

Salah Foundation Children’s Hospital
Broward Health Weston
Community Health Services
Broward Health Physician Group

DATE: 04/28/2021
TO: Robert Dillon, RN
FROM: Broward Health Institutional Review Board
RECORD NUMBER: 2021-057
STUDY TITLE: Administration of Dexmedetomidine in Patients Undergoing One Lung Ventilation for Thoracic
Lung Surgeries to Enhance Oxygenation: An Evidence-Based Education Module
RE: NOT HUMAN SUBJECT RESEARCH DETERMINATION
Dear Robert Dillon, RN:
This is to advise you that your project, “Administration of Dexmedetomidine in Patients Undergoing One Lung
Ventilation for Thoracic Lung Surgeries to Enhance Oxygenation: An Evidence-Based Education Module ” was
reviewed on behalf of the Broward Health Institutional Review Board and was declared “not research involving
human subjects” based on the definitions provided in the U.S. Department of Health and Human Services Code of
Federal Regulations found at 45 CFR 46.102.
Please note, this determination does not absolve the Principal Investigator from complying with other federal, state,
or local laws or institutional policies and procedures that may be applicable in the conduct of this project.
This determination applies to your project in the form and content as submitted to the IRB for review. Any variations
or modifications to this project involving the participation of human subjects must be approved by the IRB prior to
implementing such changes. Please maintain a copy of this determination for your records.
Thank you for submitting your project to the IRB for consideration.
The Broward Health Institutional Review Board – FWA00001248 operates in accordance with the Office of Human
Research Protections and U.S. Food and Drug Administration (FDA) regulations. The Broward Health Institutional
Review Board complies with the ICH guidelines on Good Clinical Practice (GCP) where they are compatible with the
FDA and HHS regulations.
This letter has been electronically signed in accordance with all applicable regulations, and a copy is retained
within Broward Health IRB’s records.

1600 S Andrews Avenue, Fort Lauderdale, FL 33316 , T - 954.355.4941 or 4358, F - 954.355.4930, http://www.browardhealth.org/pages/irb
IRB version dated 10.16.20
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APPENDIX F. CONSENT FORM

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT
Dexmedetomidine Administration to Improve Oxygenation During One Lung Ventilation:
A Quality Improvement Project
PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The goal of this project is to
improve patients' oxygenation during one lung ventilation, by delivering a structured educational
intervention targeting anesthesia providers, which highlights the benefits of implementing
intraoperative Dexmedetomidine co-administration during pulmonary surgeries.
DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time.
PROCEDURES
If you agree to be in the project, we will ask you to do the following things:
• Complete a pretest and a posttest questionnaire
• Review an educational PowerPoint presentation
RISKS AND/OR DISCOMFORTS
There are no foreseeable risks with you for participating in this project.
BENEFITS
The following benefits may be associated with your participation in this project: An increase in
knowledge regarding interventions to improve intraoperative oxygenation and facilitate postoperative recovery for patients undergoing one lung ventilation. The overall objective of the
program is to increase the quality of healthcare delivery, improve recovery of our patients, and
minimizing complications from pulmonary surgeries requiring one lung ventilation
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you like to receive the educational material given to the participants in this project, it
will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent provided
by law. If, in any sort of report, we might publish, we will not include any information that will
make it possible to identify you as a participant. Records will be stored securely, and only the
project team will have access to the records.
COMPENSATION & COSTS
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There is no cost or payment to you for receiving the health education and/or participating in this
project.
RIGHT TO DECLINE OR WITHDRAW
Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the right
to remove you without your consent at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
research project, you may contact Robert Dillon at 813-952-8172, rdill008@fiu.edu or Dr.
Valerie Diaz at 305-348-9027, vdiaz@fiu.edu
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights of being a subject in this project or about
ethical issues with this project, you may contact the FIU Office of Research Integrity by phone at
305-348-2494 or by email at ori@fiu.edu
PARTICIPANT AGREEMENT
I consent by participating in the survey. I have read the information in this consent form and
agree to participate in this project.

Signature: ___________________________________________

Print: _____________________________________________

Date:_____________
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APPENDIX G. PRE-TEST AND POST-TEST SURVEY

Pretest and Posttest Questionnaire:
Dexmedetomidine Administration to Improve Oxygenation During One Lung Ventilation:
An Evidence Based Education Module
INTRODUCTION
The primary aim of this QI project is to improve the knowledge of anesthesia providers
pertaining to the administration of Dexmedetomidine in patients undergoing one lung ventilation
to improve patient outcomes.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or true/false format and are meant to measure knowledge and perceptions on
Dexmedetomidine’s effects on oxygenation during one lung ventilation (OLV).
PERSONAL INFORMATION
1. Gender: Male
2. Age: 18-29

Female

Other________

30-49 50-69 70 or older

3. Ethnicity:
Hispanic

Caucasian

African American

Asian

Other_______________
4. Level of Experience:
Over 10

How many years have you been administering anesthesia?

6-10 years

3-5 years

0-2 years

50
QUESTIONNAIRE
1. One lung ventilation (OLV) is required during many ______________ procedures to
optimize surgical conditions:
a. pulmonary
b. urologic
c. neurologic
d. orthopedic
2. What are the two most significant factors that delay recovery after OLV? (Select 2)
a. poor oxygenation
b. postoperative nausea and vomiting
c. increased pain
d. obesity
3. OLV is associated with which intraoperative complications? (Select 2)
a. Wound dehiscence
b. Atelectasis
c. Aspiration
d. V/Q mismatching
4. Hypoxic pulmonary vasoconstriction (HPV) is an adaptive mechanism unique to the
pulmonary vasculature that allows for:
a. The redirection of blood flow to alveoli with higher oxygen tension
b. A reduction in V/Q mismatching during OLV
c. Increased arterial oxygenation during OLV
d. All the above
5. Which anesthetic agent is known to inhibit HPV when administered in high
concentrations?
a. Sevoflurane
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b. Propofol
c. Isoflurane
d. All the above
6. Dexmedetomidine is an:
a. Alpha 1 agonist
b. Alpha 1 antagonist
c. Alpha 2 agonist
d. Alpha 2 antagonist
7. The coadministration of Dexmedetomidine with volatile anesthetic agents or
Propofol during OLV can:
a. Reduce PaO2 but improve HPV
b. Preserve HPV and improve PaO2
c. Improve PaO2 but inhibit HPV
d. Have no effect on PaO2 or HPV
8. The proposed mechanism through which Dexmedetomidine improves oxygenation
and preserves HPV during one lung ventilation is by: (Select 2)
a. Reducing the dose of Propofol or volatile anesthetic agent administered
b. Inhibiting oxidative stress and increasing nitric oxide concentrations
c. Increasing endorphin release into the CSF
d. Altering serotonin transmission
9. How frequently do you currently implement the coadministration of
Dexmedetomidine when caring for a patient requiring one lung ventilation for
pulmonary surgery?
a. Very frequently
b. Somewhat frequently
c. Rarely

52
d. Never
10. How likely are you to adopt the coadministration of Dexmedetomidine during
pulmonary surgeries requiring one lung ventilation?
a. Very likely
b. Somewhat likely
c. Somewhat unlikely
d. Very unlikely
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APPENDIX H. EDUCATIONAL MODULE

10/18/21

Learn ing G oals
A d m in istratio n o f D exm e d e to m id in e in
P atie n ts U n d e rg o in g O n e L u n g
Ve n tilatio n fo r T h o ra c ic Lu n g S u rge rie s
to E n h a n ce O xyge n a tio n :

C linical Significance

Recognize ability to
modify anesthetic plan
to reduce complications
from thoracic lung
surgeries

L u ng ca n ce r is th e se con d m os t co m m o n ty p e o1f ca n ce r in th e U .S.
(22 8 ,8 2 0 ne w c ase s in 2 0 2 0 ).

N o n -sm a ll c e ll lu n g ca nc e r a cco un ts fo r o ve r 85 % o f ne w lu n g
c an ce r dia gn ose s.

O ve r h a lf o f p e o ple w ith n o n-sm a ll c e ll lu n g ca nc e r w ill d ie w ith in
on e ye a r of d is co ve ry; th e re fo re , a ggre ss iv e su rgica l in ter ve n tio n is
re co m m e n de d as th e sta n da rd o f ca re .

Recall physiologic
derangements which
occur during one lung
ventilation

An Evidence Based Education M odule
Robert Dillon, M SN , RN

1

2

Prob lem

3

HPV: M echanism of Action

Preservation of
Hypoxic Pulmonary
Vasoconstriction

One lung ventilation (OLV) required for pulmonary surgery is
associated with varying degrees of respiratory dysfunction
secondary to atelectasis and the maldistribution of lung
perfusion between the ventilated and nonventilated lung.

C u rre n t e v id e n c e s u g g e st s t h a t re a c t iv e o x y g e n sp e c ie s ( R O S ) a n d n itr ic o x id e p la y a fu n d a m e n t a l ro le in t h e
re g u la t io n o f h y p o x ic p u lm o n a ry v a s o c o n s t ri c t io n ( H P V ).

H y p o x ia is m o n ito re d b y p u lm o n a r y a rt e r y sm o o th m u s c l e c e lls ( PA S M C s ), a n d d u rin g h y p o x ic e p is o d e s , R O S
p ro d u c t i o n is a lte re d .

• Hypoxic Pulmonary
Vasoconstriction (HPV) is an
adaptive mechanism unique to
the pulmonary vasculature that
allows for the redirection of blood
flow to alveoli with higher oxygen
tension, thereby reducing
ventilation/perfusion
mismatching and increasing
arterial oxygenation.

This results in decreased oxygenation and increased
shunting.7

The failure to optimize respiratory function and control pain
following thoracic lung procedures increases the likelihood of
peri-operative complications that delay recovery.3

How can we prevent this?

H y p o x ia in h ib it s O 2 -s e n s it iv e v o lt a g e -g a t e d p o ta s si u m (Kv ) c h a n n e ls , w h ic h d e p o la ri ze s t h e p la sm a m e m b ra n e , t h u s
a c t iv a t in g v o lta g e g a t e d c a lc iu m (C a L ) c h a n n e ls t o i n c re a s e i n t ra c e llu la r c a l ciu m6 . T h i s in c re a s e d i n t r a c e llu la r c a lc iu m
p ro d u c e s v a s o c o n st r ic ti o n w it h in t h e p u lm o n a ry a r t e r y e x p e r ie n c in g h y p o x ia .

P u lm o n a ry v a s o c o n s t ric t io n h e lp s to d e c r e a s e b lo o d f lo w to t h e n o n -v e n t il a te d lu n g a n d in c re a s e b lo o d f lo w to t h e
v e n t il a te d lu n g , t h u s im p ro v in g o x y g e n a ti o n a n d V/ Q m a t c h in g d u rin g O LV.

H P V i s in h ib it e d b y (1 ) d ru g s t h a t p r o d u c e v a s o d ila t io n o f t h e p u lm o n a ry v a s c u la t u re / s y ste m ic v a s o d il a t in g a g e n t s
s u c h a s n it ro p r u s s id e , c a lc iu m c h a n n e l b lo c ke rs , o r B 2 re c e p to r a g o n ist s , ( 2 ) in h a la t i o n a l a n e s t h e t ic a g e n t s (3 ) v e ry
h ig h o r lo w p u lm o n a ry a rt e ry p re ss u re s ( 4 ) h y p o c a p n i a (5 ) v e ry h i g h o r l o w m i xe d v e n o u s P O 2 ( 6 ) p u lm o n a ry
in fe c t io n .

4

5

> 1.5 M AC and
w orsen shunting. 7

Intravenous
anesthetics, such as
propofol, m ight
inhibit HPV in a dosedependent manner
because of its
systemic vasodilating
effects. 8

6

D exm edeto m idine (D EX)

A nesth esia Effe cts o n H PV

Unfortunately,
inhalationa l
anesthetics are
know n to inhibit HP V
when adm inistered at

In 2004, animal
studies proposed that
Dexmedetomidine
(DEX)
may provide
bronchoprotective
effects and alter
pulmonary
inflammatory
mediators.1 0

M ethod olo gy
C IN A H L , M E D L IN E /P r o q u e s t , a n d E m b a se d a t a b a s e s w e re
re v ie w e d , u t ili z in g t h e se a rc h t e rm : (“o n e lu n g v e n t ila t io n ”
O R “ lu n g is o la t io n ” O R “ s in g le lu n g v e n t ila t io n ” O R
“ h y p o x ic p u lm o n a ry v a s o c o n s t ric tio n ” O R “ t h o r a c * ” ) A N D
( “ P re c e d e x ” O R “ D e x m e d e t o m id in e ” )

A lp h a 2 ag o n ist

4 9 7 a rt ic le s re s u lt e d , 6 9 w e re d u p lic a t e s , 4 2 8 a b s t ra c ts fo r
re v ie w

These findings
sparked an interest in
researching
Dexmedetomidine’s
effects in the setting
of hypoxia and OLV.

Alternative anesthetic
options?

4 1 3 a b st ra c t s w e r e e xc l u d e d b a s e d u p o n p re -d e t e r m i n e d
in c lu s io n / e x c lu s io n c rit e ria co n c e r n in g t h e p o p u la t io n ,
in te r v e n t io n , c o m p a ris o n , a n d o u t c o m e s o f in t e re s t to o u r
re s e a rc h .

A ft e r fu ll te x t re v i e w , 7 a rt i c le s re m a in fo r in c lu s io n in t h i s
re v ie w o f c u r re n t lite ra t u re

Lack of current clinical practice guidelines discussing
the use of Dexmedetomidine during OLV, therefore a
literature review was conducted to evaluate current
research

7

2

P ne u m o n ec to m ie s, Lo b e cto m ie s, Se gm e n tal W e d ge R e se ctio n s,
a n d VATS u sed in t he d ia gn o sis an d tre atm e nt o f lun g ca n ce r
re q u ire lu n g is o la tio n te chn iq u es to p ro vid e o ptim al s u rg ical
exp o su re , a m ot io n le ss su rgical fie ld , an d a se cu re airw ay.

Identify ways to preserve
hypoxic pulmonary
vasoconstriction during
one lung ventilation

8
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C haracteristics of Studies

Anesthetic-Sparing vs ROS/Nitric Oxide
M ediated Effects

Find ings

All studies utilized ABG sampling to collect baseline and
interval data regarding oxygenation during thoracic lung
surgeries utilizing one lung ventilation

Five of the seven RCTs compared a control group receiving
inhalational anesthetics + placebo to a study group that
received inhalational anesthetics + Dexmedetomidine.
•Desflurane (1), Isoflurane (3), Sevoflura ne (1)

Tw o studies, one utilizing
Desflurane and the other using
Isoflurane, suggest that the
im provem ent in oxygenation
seen in the DEX group m ay be
due to an anesthetic-sparring
1 3 ,1 6
effect.
S ix ou t o f sev e n article s re p orted an
im p rove m e n t in ox yge n atio n
p aram e te rs a m on gs t the g ro u p
r ece ivin g D e x m e d eto m id in e , in
c o m pa ris o n to the co n tro l gro u p . 1 3 1 5 ,1 7 -1 9

F o ur stu d ie s d e m on stra te d th at th e
im p ro ve m e nts in o xyge na tio n
a m o n g st th e D E X gro u 1p4 , w
e re
1 5 ,1 7 ,1 8
statistica lly sig nific an t.

Fo u r stu d ie s su gge st th at th e tim in g
o f the s e im pro ve m e n ts in
oxyge n atio n p ro d uc e d by
D ex m e d eto m id ine like ly co in cid e s
w ith the in itiation o f hy po xic
p ulm o n ary va so c on s tric tion , thu s
sig n ify in g th at D E X m ay play a ro le in
th e p re se rva tio n o r a ugm e n tation o f
H P V. 1 5 , 1 7 , 1 8 , 1 9

A study utilizing Isoflurane and
DEX m easured levels of reactive
oxidative species and nitric oxide
concentrations during O LV
suggested that DEX m ay
attenuate intrapulmonary
shunting and im prove
oxygenation by inhibiting
oxidative stress and increasing
nitric oxide concentra1 tions
in the
ventilated. 7

Two of the seven RCTs compared a control group receiving
Propofol + placebo to a study group that received Propofol
+ Dexmedetomidine.

10
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Take H om e Po ints

C onclusion

• Cons:
• Limited # of research articles available
• Disagreement on mechanism of action

DEX (1.0 m cg/kg IV over
10 min, then
0.7m cg/kg/hr continuous
infusion), Rem ifentanil
0.1-0.2 m cg/kg/min, and
Isoflurane titrated
to BIS
40-60. 1 4

Nebulized DEX
(0.5m cg/kg, 1m cg/kg, or
2m cg/kg) + Propofol
infusion titrated to
ma intain BIS 40-60 +
Cisatricurium.

15

DEX loading dose
1m cg/kg over 10 min IV,
followed by
0.5m cg/kg/hr
m aintenance infusion,
Titration of Sevoflurane
to m aintain BIS 40-60. 1 8

DEX (1m cg/kg bolus over
10 min IV, follow ed by
0.7mcg/kg/hr infusion) +
Rem ifentanil 0.1-0.2
m cg/ kg/min and 1.02.0% Isoflurane titrated
to BIS 40-60. 1 7

• Dosing Regim ens Utilized à à à

13

The co-adm inistration of Dexm edetom idine during thoracic lung surgeries
requiring one lung ventilation im proves oxygenation intraoperatively. 1 4 ,1 5 ,1 7 ,1 8

D exm edetom idine adm inistration has also been show n to extend its benefits on
arterial oxygenation into the PACU setting, and can even im prove pulm onary
function on PO D 1 and 2.3
A synergistic anti-nociceptive action occurs w ith the co-adm inistration of alpha
2 agonists, like Dexm edetom idine, and m u receptor agonists, like opioids, w hich
reduces overall opioid consum ption and im proves patient satisfaction. 3
These benefits of Dexmedetom idine adm inistration ultim ately facilitate faster
discharge from PACU and significantly reduced hospital length of stay. 3

14

12.Cook DA, West CP. Conducting systematic reviews in medical education: A stepwise approach. M ed Ed uc. 2012;46:943-952.
doi:10.1111/j.1365-2923.2012.04328.x

•

13.Kernan S, Rehman S, Meyer T, Bourbeau J, Caron N, Tobias JD. Effects of dexmedetomidine on oxygenation during one-lung ventilation for
thoracic surgery in adults. J M inim A ccess Surg. 2011;7(4):227-231.

•

14.Xia R, Yin H, Xia ZY, Mao QJ, Chen G, Xu W. Effect of intravenous infusion of dexmedetomidine combined with inhalation of isoflurane on
arterial oxygenation and intrapulmonary shunt during single-lung ventilation. Cell B iochem B io phys.

•

15.Xu B, Gao H, Li D, Hu C, Yang J. Nebulized dexmedetomidine improves pulmonary shunt and lung mechanics during one-lung ventilation: A
randomized clinical control trial. PeerJ. 2019;8:e9247. doi:10.7717/peerj.92472013;67:1547-1550.
16.Asri S, Hosseinzadeh H, Eydi M, Marahem M, Dehghani A, Soleimanpour H. Effect of dexmedetomidine combined with inhalation of isoflurane
and oxygenation following one-lung ventilation in thoracic surgery. An esth Pa in M ed. 2020;10(1):e95287.

•
•

17.Xia R, Xu J, Yin H, et al. Intravenous infusion of dexmedetomidine combined isoflurane inhalation reduces oxidative stress and potentiates
hypoxia pulmonary vasoconstriction during one-lung ventilation. M ed iato rs In flam m . 2015;2015:238041. doi:10.1155/2015/238041.

•

18.Lee SH, Kim NK, Lee CY, Ban MG, Oh YJ. Effects of dexmedetomidine on oxygenation and lung mechanics in patients with moderate chronic
obstructive pulmonary disease undergoing lung cancer surgery. Eu r J Anaesth esio l. 2016;33:275-282. doi:10.1097/EJA.0000000000000405
19.Gu Z, Yang J, Xin L, Xu J, Yang Y, Wang Z. Dose-dependent effects of dexmedetomidine during one-lung ventilation in patients undergoing
lobectomy. Int J Clin Exp M ed. 2017;10(3):5216-5221.

•
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Thank You!
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A study utilizing Propofol
reported that Dex infusion did
not significantly decrease the
am ount of Propofol needed to
m aintain adequate depth of
anesthesia, thus the m echanism
of Dexmedetomidine’s
improvem ents in oxygenation
during OLV is not related to1 an
anesthesia-sparing effect. 9
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Refere nces
•

group; therefore the
im provement in oxygenation
seen in the DEX group m ust be
related to the mechanisms of
Dexmedetom idine and not 1an
8
anesthetic-sparing effect.

12

• Pros:
• Six of the seven articles observed an
increase in oxygenation during OLV
w ith D exm edetom idine coadm inistration
• 4 of 7 articles found the improvements in
oxygenation to be statistically significant

One study reported that there
wa s no significant decrease in
Sevoflurane concentration
adm inistered betw een the
Dexmedetom idine and control

2

